

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 November 2021 (25.11.2021)



(10) International Publication Number
WO 2021/236658 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/28 (2006.01)
A61K 47/68 (2017.01) C07K 16/40 (2006.01)

(21) International Application Number:

PCT/US2021/032990

(22) International Filing Date:

18 May 2021 (18.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/026,883 19 May 2020 (19.05.2020) US
63/037,241 10 June 2020 (10.06.2020) US

(71) Applicant: **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Strasse 173, 55216 Ingelheim am Rhein (DE).

(72) Inventors: **BORGES, Eric**; Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **GUPTA, Pankaj**; C/o VP, IP, Boehringer Ingelheim USA Corporation, 900 Ridgebury Road, PO Box 368, Ridgefield, Connecticut 06877 (US). **ROWE, Daniel Christopher**; C/o VP, IP, Boehringer Ingelheim USA Corporation, 900 Ridgebury Road, PO Box 368, Ridgefield, Connecticut 06877 (US). **SCHEER, Justin M.**; C/o VP, IP Boehringer Ingelheim USA Corporation, 900 Ridgebury Road, PO Box 368, Ridgefield, Connecticut 06877 (US). **SOUABNI, Abdallah**; Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein (DE).


al GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **TIRAPU, Inigo**; Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **TUMANG, Joseph Ronald**; C/o, VP, IP Boehringer Ingelheim USA Corp., 900 Ridgebury Road, Po Box 368, Ridgefield, Connecticut 06877 (US).

(74) Agent: **LOCKENOUR, Andrea** et al.; Boehringer Ingelheim USA Corporation, 900 Ridgebury Road, PO Box 368, Ridgefield, Connecticut 06877 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: BINDING MOLECULES FOR THE TREATMENT OF CANCER



(57) Abstract: This invention relates to binding molecules that bind specifically to CD137 and FAP and their use in medicine, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of cancer.

[Continued on next page]

WO 2021/236658 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*